If you have questions about the work we do or are interested in helping us create a world free of psoriasis, please contact us using the information below.
General information Christy Langan, CEO
Finance and accounting Michele Borsa, Administrative Coordinator
Media Erika Fey, Senior Marketing and Communications Manager
Events and meetings Amanda Bledsoe, Senior Meeting and Events Planner
Partnership opportunities Tina A. Burke, Director of Corporate Relations
Education programs Nicora Gardner, MSW, Senior Education and Outreach Manager
Medical affairs Peter van de Kerkhof, MD, PhD, Chief Medical Officer
UPCOMING EVENT The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory? Wednesday, September 18, 2019 2:00 pm - 6:00 pm Bordeaux, france Register Now
IPC Psoriasis Review Newsletter IPC's bi-annual review of the latest manuscripts in the field of psoriasis. Read the latest issue
IPC's bi-annual review of the latest manuscripts in the field of psoriasis.
Psoriasis News Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis8/20/2019 10:08:00 AMEli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease8/6/2019 11:36:00 AMCelgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Updated Disease Classification System Adopted by the World Health Organization8/1/2019 7:19:00 AMOn 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022. FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)8/1/2019 7:09:00 AMSamsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below. More News